In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU’s IVDR Clinical Evidence Comes Under The Microscope

Executive Summary

Do you know what is required when it comes to providing clinical evidence for IVDs in the EU? Consultants at Maetrics explain how, given that the majority of  IVDs are about to find themselves in a higher risk class, there is a steep learning curve ahead. There will also be a scramble for the limited notified body resources available.

You may also be interested in...



Expert Panel Discusses Impact Of Stricter US, EU Data Privacy Laws On Medtech Industry

An expert panel at the AdvaMed Digital MedTech Conference discussed the impact of new privacy rights and data protection, in particular CCPA and GDPR, on medtech companies and ways for companies to deal with the challenge of compliance.

Mylan Makes Decision On Potential First Botox Biosimilar

Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.

Mylan Pulls Generic Gilenya Application Over Study Concerns

Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.

Topics

UsernamePublicRestriction

Register

PS142283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel